Phase I Safety, Tolerability, and Pharmacokinetics Study of 2ccPA in Patients With Symptomatic Knee Osteoarthritis
Latest Information Update: 04 Nov 2021
At a glance
- Drugs 2ccPA (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Orient Europharma
Most Recent Events
- 29 Apr 2021 Status changed from recruiting to completed.
- 14 Sep 2020 Planned End Date changed from 1 Dec 2020 to 30 Apr 2021.
- 14 Sep 2020 Planned primary completion date changed from 1 Aug 2020 to 30 Apr 2021.